Form 4: Halozyme Therapeutics SVP, Chief Technical Officer, Michael J. LaBarre, Reports Stock Option Exercises
SEC Form 4 Filing
Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, exercised stock options to acquire a total of 11,618 shares of common stock on March 26, 2024.
Summary
- On March 26, 2024, Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, exercised options to purchase common stock.
- He acquired 8,436 shares at $12.07 per share, 292 shares at $16.78 per share, and 2,890 shares at $8.11 per share.
- Following these transactions, LaBarre directly owns 168,176 shares of Halozyme Therapeutics common stock and holds options for 61,715 shares.
Sentiment
Score: 6
Explanation: Neutral sentiment. The filing is a standard disclosure of stock option exercises, which doesn't inherently indicate positive or negative sentiment. The executive's decision to exercise options suggests a belief in the company's value, but it's a routine transaction.
Positives
- The exercise of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies as part of executive compensation packages. These transactions are closely monitored by investors for insights into management's view of the company's prospects.
Comparison to Industry Standards
- Stock option exercises are a standard component of executive compensation packages in the biotechnology industry, used by companies like Amgen, Gilead Sciences, and Regeneron to incentivize and retain key personnel.
- The vesting schedules and exercise prices are typical for stock options granted to executives in similar roles at comparable companies.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it slightly increases the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 02/03/2016 | Date of grant for options to purchase 2,890 shares, vesting quarterly. |
| 02/22/2017 | Date of grant for options to purchase 8,436 shares, vesting quarterly. |
| 07/02/2018 | Date of grant for options to purchase 292 shares, vesting quarterly. |
| 03/26/2024 | Date of transaction: Exercise of stock options and filing date of Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.